Neoadjuvant Nivolumab Yields High Response in Newly Diagnosed NSCLC
Neoadjuvant nivolumab combo proved safe while yielding high response rates in patients with NSCLC.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
SUBSCRIBE: Print / eNewsletter
Neoadjuvant Nivolumab Yields High Response in Newly Diagnosed NSCLCApr 25, 2018 Neoadjuvant nivolumab combo proved safe while yielding high response rates in patients with NSCLC. |
Whole-Genome Analyses Expand Genetic Picture of Prostate CancerApr 25, 2018 A study found some mutations that are already targeted by approved or investigational drugs for prostate cancer, along with dozens of targets that should be considered as candidates for future trials. |
ctDNA Increase May Predict Regorafenib Response in Advanced CRCApr 25, 2018 In this video, Pashalina Kehagias discusses how an early increase in ctDNA may predict a poor response to regorafenib in advanced CRC. |
Novel TKI Plus Chemo Dramatically Shrank Advanced Head & Neck TumorsApr 25, 2018 AZD1775, a small-molecule, WEE1-targeting TKI, significantly shrunk tumors when administered in combination with cisplatin and docetaxel in a phase I trial. |
Pembrolizumab Plus Chemo Improved Survival in Advanced NSCLCApr 24, 2018 In KEYNOTE-189, a pembrolizumab/chemo combination yielded OS and PFS benefits in patients with advanced NSCLC. |
Xenograft Platform Could Lead to Mouse-Based Clinical TrialsApr 24, 2018 In this video, Dr. Edison Liu describes a novel patient-derived xenograft platform that might enable development of a mouse-based clinical trials program. |
Prognostic Tool Can Guide Extended Endocrine Therapy in ER+ Breast CancerApr 23, 2018 A simple prognostic tool could be used to identify patients with HR-positive breast cancer who underwent 5 years of endocrine treatment and who might be at higher risk of late distant recurrence. |
Forecasting PARP Inhibitor Resistance in Breast Cancer PatientsApr 23, 2018 In this video, Dr. Elizabeth Swisher reviews the use of PARP inhibitors in ovarian cancer, and the importance of understanding how resistance to these agents develops. |
Late Diagnosis: Cause of Poorer Survival in Alcohol-Related Liver Cancer?Apr 23, 2018 Patients with alcohol-related HCC had worse OS than other HCC patients, mainly due to poorer liver function and more unfavorable tumor characteristics at diagnosis. |
Cancer Care Becoming More Patient-CentricApr 20, 2018 In this podcast, Dr. Debra Patt discusses trends in cancer care, including how treatments are becoming more personalized and less toxic. |